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Abstract
Background: Prostate epithelial cells depend on androgens for survival and function. In (early) prostate cancer (PCa)
androgens also regulate tumor growth, which is exploited by hormonal therapies in metastatic disease. The aim of the
present study was to characterize the androgen receptor (AR) response in hormonal therapy-resistant PC346 cells and
identify potential disease markers.
Methodology/Principal Findings: Human 19K oligoarrays were used to establish the androgen-regulated expression profile
of androgen-responsive PC346C cells and its derivative therapy-resistant sublines: PC346DCC (vestigial AR levels), PC346Flu1
(AR overexpression) and PC346Flu2 (T877A AR mutation). In total, 107 transcripts were differentially-expressed in PC346C
and derivatives after R1881 or hydroxyflutamide stimulations. The AR-regulated expression profiles reflected the AR
modifications of respective therapy-resistant sublines: AR overexpression resulted in stronger and broader transcriptional
response to R1881 stimulation, AR down-regulation correlated with deficient response of AR-target genes and the T877A
mutation resulted in transcriptional response to both R1881 and hydroxyflutamide. This AR-target signature was linked to
multiple publicly available cell line and tumor derived PCa databases, revealing that distinct functional clusters were
differentially modulated during PCa progression. Differentiation and secretory functions were up-regulated in primary PCa
but repressed in metastasis, whereas proliferation, cytoskeletal remodeling and adhesion were overexpressed in metastasis.
Finally, the androgen-regulated genes ENDOD1, MCCC2 and ACSL3 were selected as potential disease markers for RT-PCR
quantification in a distinct set of human prostate specimens. ENDOD1 and ACSL3 showed down-regulation in high-grade
and metastatic PCa, while MCCC2 was overexpressed in low-grade PCa.
Conclusions/Significance: AR modifications altered the transcriptional response to (anti)androgens in therapy-resistant
cells. Furthermore, selective down-regulation of genes involved in differentiation and up-regulation of genes promoting
proliferation and invasion suggest a disturbed balance between the growth and differentiation functions of the AR pathway
during PCa progression. These findings may have implications in the current treatment and development of novel
therapeutical approaches for metastatic PCa.
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Introduction
Prostate cancer is the most frequently diagnosed non-cutaneous
malignancy in men and the second leading cause of cancer deaths in
the western countries [1]. Prostate cancer is a highly heterogeneous
condition, exhibiting a wide range of biological and clinical
manifestations. While some patients develop an asymptomatic
disease course and rather die with the cancer than from the cancer,
others present with a more aggressive and/or more advanced
disease at the time of diagnosis [2]. When the tumor is confined to
the prostate, it can be efficiently treated by radical surgery and/or
radiation therapy, but once the tumor has disseminated, systemic
therapy is required. Since prostate cancer cells require androgens
for their survival and growth, the golden standard for the treatment
of evasive prostate tumors is androgen ablation through chemical or
surgical castration, which may be combined with the administration
of androgen receptor (AR) antagonists [2]. Most patients will benefit
from this hormonal therapy, the tumors may shrink and the
symptoms ameliorate. However, eventually all cancers will become
resistant and recur as therapy-refractory or castration-resistant
disease, for which at the moment no curative treatment exists [3,4].
The AR pathway is very versatile, being involved in many biological
processes including cellular proliferation, regulation of apoptosis
and differentiation [5]. The balance between these different
functions dictates the homeostasis of the prostatic gland. A pertinent
question is how prostate cancer cells that are initially dependent on
androgens can resume growth in an androgen-deprived environ-
ment. One possibility is that prostate cancer cells achieve this by
adapting their AR pathway to the low androgen/high antiandrogen
levels, for example by mutation, amplification or truncation to a
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constitutively active AR, deregulation of AR cofactors and/or
intratumoral androgen production [6,7]. On the other hand, cancer
cells may activate alternative growth pathways, while shutting down
tumor suppressors and apoptotic signals [6,7].
In the present study, we focused on the role of the AR pathway
in prostate cancer progression. The expression pattern of
androgen-regulated genes in androgen-responsive and castration-
resistant cell lines was established, with the goal to: (i) determine
whether the AR pathway is still functionally active in the hormonal
therapy-resistant PC346 cells; (ii) identify the mechanism(s) by
which the AR pathway may be adjusted to the low androgen/high
antiandrogen levels; (iii) identify androgen-regulated genes that
could potentially be used in the diagnosis/prognosis of prostate
cancer or as a therapeutic target. For this purpose, we used
microarray technology to characterize the transcriptional program
activated by the synthetic androgen R1881 and the antiandrogen
hydroxyflutamide. As model system we used the PC346 cell lines
(Table 1): the androgen-responsive PC346C parental cell line and
its therapy-resistant derivative sublines PC346DCC, PC346Flu1
and PC346Flu2 [8]. These castration-resistant sublines reproduce
common AR modifications observed in therapy-resistant disease:
AR down-regulation (PC346DCC), AR mutation (PC346Flu2)
and AR overexpression (PC346Flu1), making it a unique and
valuable model for this study.
Methods
Ethics Statement
Normal and tumor samples from patients were obtained from
the frozen tissue bank of the Erasmus Medical Center (Rotterdam,
the Netherlands). The specimens were collected between 1984 and
2001. The experimental protocols were approved by the Erasmus
MC Medical Ethics Committee according to the Medical
Research Involving Human Subjects Act.
Reagents and cell lines
The basic culture medium used in the maintenance of PC346
cell lines consisted of DMEM-F12 medium (Cambrex BioWhi-
taker, Belgium) supplemented with 2% fetal calf serum (FCS; PAN
Biotech GmbH, Aidenbach, Germany), 1% insulin-transferrin-
selenium (Gibco BRL), 0.01% bovine serum albumin (Boehringer
Mannheim, Germany), 10 ng/ml epidermal growth factor (Sigma-
Aldrich), penicillin/streptomycin antibiotics (100 U/ml penicillin,
100 mg/ml streptomycin; BioWhitaker, Belgium); plus the
following additions: 100 ng/ml fibronectin (Harbor Bio-Products,
Tebu-bio, The Netherlands), 20 mg/ml fetuine (ICN Biomedicals,
The Netherlands), 50 ng/ml choleratoxin, 0.1 mM phosphoetha-
nolamine, 0.6 ng/ml triiodothyronine and 500 ng/ml dexameta-
son (all from Sigma). PC346C cells were maintained in culture in
the complete medium mentioned above, supplemented with
0.1 nM 17-methyltrienolone (R1881; NEN, Boston MA, USA).
PC346DCC selection medium was supplemented as described
above, but depleted from androgens by using dextran-coated
charcoal (DCC) treated FCS. PC346Flu1 and PC346Flu2 culture
medium was also androgen depleted by using 2% DCC-FCS, and
supplemented with 1 mM of hydroxyflutamide (OH-flutamide,
Schering-Plough Research Institute, New Jersey, USA). For the
hormone stimulations, a simplified version of the culture medium
was used, containing 2% DCC- FCS without the above mentioned
additions (minimal medium). Cells were grown in T25 PrimariaTM
tissue culture flasks (BD Biosciences Benelux N.V, The Nether-
lands) at 37uC under 5% CO2 humidified atmosphere.
Hormone stimulations and expression microarray
analysis
Cells were seeded in their respective selection medium to reach
,50% confluency and allowed to attach overnight. The next day,
medium was replaced with 2% DCC-FCS in minimal medium and
cells were starved for 48 h, to bring AR activity to basal levels before
the hormone stimulations. Subsequently, cells were stimulated with
either vehicle, 1 nM R1881 or 1 mM OH-flutamide for 4, 8 or 16 h.
After stimulations, cells were rinsed twice with PBS and stored at
220uC until RNA isolation. Total RNA was isolated with RNAzol
B reagent (Campro Scientific, Veenendaal, The Netherlands) and
further purified through RNeasy columns (Qiagen) with on-column
DNA digestion, according to the manufacturer’s protocol. RNA
quality was checked on 1% agarose gel.
Cy3- or Cy5-labelled RNA probes were produced by incorpo-
rating amino-allyl UTP during RNA amplification, followed by
coupling to N-hydroxysuccinimide modified dye. Briefly, 3 mg
RNA was used for a T7-based linear mRNA amplification
protocol, described previously [9]. Amino-allyl UTP, plus equal
amount of unmodified rUTP, was incorporated into aRNA with
T7 Megascript Kit (all from Ambion), according to manufacturer’s
protocol. Amplified RNA was purified and concentrated using
Microcon-YM 30 columns (AmiconH) to rinse three times with
300 ml RNAse-free water. Finally, 2 mg aminoallyl-modified RNA,
in a maximum of 3.33 ml of RNAse-free water, was incubated with
1.66 ml sodium bicarbonate buffer (0.3 M, pH 9) and 5 ml Cy3- or
Cy5-dye (CyScribe Post-Labeling Kit, Amersham, NJ, USA), for
1 h in the dark at room temperature. Reaction was stopped with
5 ml 4 M hydroxylamine HCl (Sigma), contra-labelled probes were
combined and purified/concentrated using Microcon-YM 30
columns. Probe was collected in 5–15 ml final volume and
resuspended in 80 ml Ambion hybridization buffer number 1.
For the microarray we used double-dye oligoarrays representing
about 15,000 human genes, on which labelled hormone-stimulated
RNA was cohybridized with its contra-labelled time-matched
vehicle (ethanol) control. Two microarrays were performed per
Table 1. Characteristics of the PC346 cell line panel: AR status and hormone response.
PC346C PC346DCC PC346Flu1 PC346Flu2
AR status wt AR AR low AR high T877A AR
PSA expression + + - + + + +
Growth on steroid-stripped medium -/+ + + + + +
Growth with 0.1 nM R1881 + + + + + + +
Growth with 1 mM OH-flutamide -/+ + + + + + +
The detailed characterization of the PC346 cell lines was the aim of a previous manuscript [8].
doi:10.1371/journal.pone.0023144.t001
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condition: in one experiment the stimulated samples were labeled
with Cy3 and the unstimulated reference with Cy5, in the other
experiment in vice-versa (dye-swap); this was done to exclude dye-
preferential binding to oligonucleotides on the microarray. In
addition, two independent cell passages were used for each of these
experiments, to account for the biological variability.
The oligoarrays used in this study were produced at the
Erasmus Center for Biomics. Briefly, a human 18,584 oligonucle-
otides library (Compugen, Sigma-Genosys) was spotted on
aminosilane slides using a Virtek Chipwriter Professional arrayer
(Virtek Vision International, Waterloo, Canada). Control spots
included landmarks, spotting buffer, alien oligonucleotides (Spot-
Report Alien Oligo Array, La Jolla, Stratagene), poly d[A]40–60,
salmon sperm DNA, and human COT-1 DNA. Before the
hybridization, microarray slides were prehybridized in 5x SSC,
0.05% SDS, 4% BSA solution for 30 min at 45uC, washed twice
with RNAse-free water for 2 min, rinsed with isopropanol and
spin-dried for 3 min at 1500 g. Microarray hybridizations were
performed overnight at 45uC, with continuous agitation, in a
HS4800 Hybridization Station (Tecan Benelux BV). Finally, the
arrays were washed automatically in the Hybridization Station
using: 2x SSC/0.05% SDS (at 45uC), 1x SSC and 0.2x SSC (at
room temperature), and dried under a stream of N2, before
scanning.
Data extraction and analysis
Arrays were scanned in a ScanArray Express HT scanner
(Perkin Elmer, Nederland BV) and spot intensities were quantified
using Imagene software (Bio Discovery Inc, El Sequndo, CA,
USA). To balance Cy3 and Cy5 spot intensities, Loewess
normalization per subarray was performed using limma-package
(http://bioinf.wehi.edu.au/limma/) from Bioconductor (http://
www.bioconductor.org) [10,11]. To scale between arrays, the
global median intensity per array was set at 1000. Dye intensities
below 200 were then thresholded at 200, to minimize noise and
make fold-change on the low-intensity range more robust against
outliers. Spots with intensities below the threshold (200) for both
Cy3 and Cy5 channels, in more than 50% (.3/6) of the arrays for
each time-course, were excluded from the analysis. Sample to
vehicle-control ratios were then calculated and 2log transformed.
Spots that showed opposite effects for the dye-swap/biological
replicates were excluded from further analysis; effects were called
opposite if the mean 2log ratio for the three time-points tested
were $0,5 for one dye and below #-0,5 for the dye-swap.
Following normalization and all the above-mentioned quality
controls, the 2log intensity ratios from both replicates were
averaged for each time point. This data was stored in SRS7
(Sequence Retrieval System version 7, Lion Bioscience AG,
Heidenberg, Germany) [12], which was also used for the
comparisons with other previously published/publicly available
databases [13,14,15,16,17,18,19,20,21,22,23,24].
Hierarchical clustering and data visualization was performed
using Cluster and TreeView programs (Eisen Labs: http://rana.
lbl.gov), respectively. Significance Analysis of Microarrays (SAM;
http://www-stat.stanford.edu/˜tibs/SAM) was used to determine
which genes were statistically different between stimulated samples
and non-stimulated references. Gene ontology clustering was
performed using Database for Annotation, Visualization and
Integrated Discovery (DAVID: http://david.abcc.ncifcrf.gov)
[25,26]. The pathway and functional analyses were generated
through the use of Ingenuity Pathways Analysis (IngenuityH
Systems, www.ingenuity.com).
All the microarray data is MIAMI compliant and has been
deposited in the Gene Expression Omnibus repository (http://
www.ncbi.nlm.nih.gov/geo/), under the GEO accession number
GSE22914.
cDNA synthesis and RT-PCR analysis
Total RNA was isolated as described above and cDNA was
synthesized using MMLV-reverse transcriptase kit and Oli-
go(dT)12–18 primer (Invitrogen), according to manufacturer’s
protocol. cDNA samples were stored at 220uC. For the validation
of the microarray results, quantitative real-time PCR analysis was
performed using an ABI Prism 7700 Sequence Detection System
(Applied Biosystems, Foster City, CA). KLK2, PART1, TPD52,
FKBP5, GPR88, STEAP1, TRIB1 and ID3 were quantified with
ABsolute QPCR SYBR Green ROX Mix (Thermo Scientific) and
330 nM of each primer, according to the manufacturer’s protocol.
Primers were designed using the computer program Oligo Primer
Analysis Software version 6.22 (Molecular Biology Insights Inc,
USA). Gene specificity was checked by BLAST and, whenever
possible, intron-spanning primers were chosen to avoid amplifi-
cation of contaminating DNA. Primer sequences are described in
Table 2. TMPRSS2, PSA and GAPDH were quantified by
TaqMan real-time PCR analysis, using ABsolute QPCR ROX
Mix (Thermo Scientific). TMPRSS2 (assay ID Hs00237175_m1)
and GAPDH (assay ID Hs99999905_m1) kits were purchased
from Applied Biosystems and run following the manufacturer’s
instructions. PSA was quantified as described previously [8]. For
each gene, a standard curve was constructed from serial dilutions
of a reverse-transcribed PC346 RNA pool, which was then used to
determine the quantity of target message from the threshold cycle
(Ct) value. The GAPDH housekeeping gene was used as
endogenous control.
For the quantitative PCR analysis of the human tissue panel,
normal and tumor samples from patients were obtained from the
frozen tissue bank of the Erasmus Medical Center (Rotterdam, the
Netherlands). Additional information about these specimens was
provided previously [27]. TaqMan real-time PCR analysis was
performed in an ABI Prism 7700 Sequence Detection System
(Applied Biosystems, Foster City, CA), using AmpliTaq Gold DNA
polymerase (Applied Biosystems), according to manufacturer’s
specifications. Validated primers and probes from TaqMan Gene
Expression Assays (Applied Biosystems) were used for quantification
of ACSL3 (Hs01071247_m1), MCCC2 (Hs00223257_m1), EN-
DOD1 (Hs00826684_m1) and GAPDH (Hs99999905_m1), ac-
cording to the PCR settings provided by Applied Biosystems. PBGD
was quantified using 330 nM of primers forward: 59-CAT GTC
TGG TAA CGG CAA TG-39 and reverse: 59-GTA CGA GGC
TTT CAA TGT TG-39 primers, in Power SybrGreen PCR Master
Table 2. Primer sequences used in the quantitative RT-PCR
analysis.
Gene Forward primer Reverse primer
KLK2 AGATGAAGACTCCAGCCAT GATACCTTGAAGCACACCA
PART1 GAGCCAGCCAATCACTT AGCAGCACTCAGGCGT
TPD52 TTTCAATGTGTTGGAAACTGTAA TAGAATACCTTGGCCTCTATGC
GPR88 CCAAGGCGTCTCTTTAAGT ATGGCAACTCATACTGGTG
FKBP5 GAATACACCAAAGCTGTTGA CTCTTCCTTGGCATCCT
STEAP1 AGAAGATGCCTGGATTGA CTTCTTCCTCAAGCATGG
ID3 GGAGCTTTTGCCACTGACTC GCTCCTGAGCACCAGGTTTA
TRIB1 ATGGGACTTTGAGAAGAGG GCCATCTCACTGTTCACAT
doi:10.1371/journal.pone.0023144.t002
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mix (Applied Biosystems), according to thermocycling protocol
recommended by the manufacturer. Transcript quantities for each
sample were normalized against the average of two endogenous
references and relative to a calibrator. The two housekeeping genes
used as endogenous references were PBGD and GAPDH; a mixture
of cDNAs from prostate carcinoma xenografts was used as the
calibrator. Graphs and statistics were performed with GraphPad
Prism (version 3.0). P-values ,0.05 were considered significant.
Results
Gene expression pattern of PC346 cells treated with
R1881 and hydroxyflutamide
To characterize the expression profile of androgen receptor
target genes in prostate cancer cells, we used expression
microarray analysis on the PC346 cell line panel incubated with
the androgen analogue R1881 or the antiandrogen OH-flutamide.
The PC346 model system is composed of four cell lines: the
androgen-sensitive PC346C and three hormonal therapy-resistant
sublines, derived from the parental PC346C by long-term
androgen ablation (PC346DCC), supplemented with the antian-
drogen OH-flutamide (PC346Flu1 and PC346Flu2). All these
sublines exhibit different properties with respect to AR status and
responsiveness (summarized in Table 1) [8].
For the expression analysis we stimulated the cells with 1 nM
R1881 or 1 mM OH-flutamide for 4, 8 or 16 h and cohybridized
the labeled RNA with its time-matched vehicle (ethanol) control.
Two microarrays were performed per condition, using two
independent cell passages in dye-swap, to account for the
biological variability and potential dye-preferential effects. Early
time-points were chosen in order to enrich for primary AR targets,
and minimize indirect secondary targets.
The two replicates per time-point were averaged and a total of
107 differentially-expressed transcripts were selected to constitute
the AR pathway signature: 74 up-regulated and 33 down-
regulated by R1881 and/or OH-flutamide (Tables 3, 4, 5, 6).
Spots were considered to be differentially-expressed if the absolute
2log ratio$0.5 (ratio$1.42 or#0.71) for all three time-points, for
at least one cell type. Significance Analysis of Microarrays (SAM)
was used to determine which genes were statistically different
between stimulated samples and non-stimulated references. In the
experimental design, we chose to perform the hormonal
stimulations at 3 different time points so that transcripts with a
faster or slower response would not be missed. However, the time
effect was negligible: most androgen-regulated transcripts were
differentially expressed at all time three time points and for the
statistical analysis we decided to pool all the 3 time points per
condition. In total, there were 253 SAM significant genes, with a
false discovery rate (FDR) set at 0.05 (Tables S1, S2, S3, S4). From
our 107 signature transcripts, considered differentially-expressed
according to the above-mentioned selection criteria, 77 were
statistically significant by SAM. Indeed, the expression of the
remaining 30 (28%) transcripts of our AR-target signature varied
across the 3 time-points, so that these did not reach statistical
significance in the pooled SAM analysis. This variation cannot be
explained by a apparently predominant kinetic pattern, nor can it
be attributed to the 4 h time point in particular. Since temporal
regulation was observed for such few transcripts, no analysis was
performed on the dynamics of gene-expression variation across
time. The expression ratios presented in the tables and Figure 4
are from the average of all three time-points per condition. Finally,
the fact that a considerable number of SAM significant transcripts
were not included in our AR-regulated signature was due to our
choice to set the 2log ratio threshold at 0.5.
The androgen-sensitive PC346C subline responded to the
R1881 stimulation with increased expression of 18 genes, while 2
were down-regulated. Among these are some well-known AR
regulated genes, such as KLK2, STEAP1, TMPRSS2 and
FKBP5. The therapy-resistant sublines showed distinct responses
to R1881 and OH-flutamide. PC346Flu1, which expresses 4-fold
higher AR levels than the parental cell line, showed a ‘‘super-
activation’’ of the AR pathway by R1881, not only in the
magnitude of the gene expression but also in the number of
regulated genes (20 androgen-regulated genes in the parental
PC346C versus 91 in PC346Flu1). Conversely, the PC346DCC
subline, which expresses residual levels of AR protein, showed no
detectable changes in gene expression after the hormone
treatments. Neither PC346C, PC346DCC nor PC346Flu1
showed significant alterations in the transcriptional profile in
response to OH-flutamide. In contrast, PC346Flu2 cells, which
express the T877A mutated AR, responded to both R1881 and
this antiandrogen, although the response to the latter was weaker
(14 genes up-regulated by R1881 versus 8 up-regulated by OH-
flutamide; Tables 3 and 5, respectively).
Validation of the microarray data
The microarray data was validated by two approaches: an
experimental approach using quantitative RT-PCR, and a
bioinformatics approach linking our gene signature to a set of
publicly available databases on androgen response. We selected 10
androgen-regulated genes to be further validated by quantitative
RT-PCR: PSA, KLK2, PART1, TPD52, GPR88, FKBP5,
TMPRSS2, STEAP1, ID3 and TRIB1. It is worth noting that
our microarray analysis did not detect regulation of PSA
expression in response to the hormonal treatments, but since this
is a prominent AR target gene, it was included in the RT-PCR
validation step. The quantitative PCR analysis confirmed the
differential expression of all selected genes in the same direction
predicted by the microarray analysis (Fig. 1). Furthermore, the
RT-PCR also showed a stronger effect of the hormone-treatment
on the PC346Flu1 cell line, in contrast to the almost absent
induction of PC346DCC cells, when compared to the parental
PC346C, for most genes analysed. As observed in the microarray
assay, PC346Flu2 showed equivalent responses to R1881 and
OH-flutamide for many regulated genes (Fig. 1, Tables 3, 4, 5, 6).
In the past years, a series of studies have been published that
analyzed gene expression in response to androgens stimulation in
cell lines and xenografts (Table 7). Of the 107 transcripts in our
signature, 73 were present in at least 3 of the 5 databases and were
included for further analysis. More than 90% of the linked genes
overlapped with previously reported androgen-regulated targets.
Genes with the strongest inductions in our present work also
showed consistently high inductions in multiple previous reports,
suggesting that the products of these genes may play a basic role in
the biological function of the prostate (Fig. 2). Using our unique
cell line panel, we were able to identify novel androgen-responsive
genes such as MAFB, KLF9, NFIB, STBD1, BIK and HLX.
Biologic processes coordinated by the AR pathway
The androgen-regulated signature genes were classified accord-
ing to Gene Ontology (GO) Biological Processes using the
Database for Annotation, Visualization and Integrated Discovery
(DAVID: http://david.abcc.ncifcrf.gov) [25,26].
Consistent with the physiological roles of androgens, this
approach revealed that the AR target genes selected in the present
study operate in the regulation of transcription and intracellular
signaling pathways, the metabolism of proteins, lipids and
carbohydrates, and the regulation of cell proliferation and
AR Pathway in Therapy-Resistant PCa Cells
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Table 3. List of genes up-regulated by R1881.
GenBank ID HUGO_Symbol Cytoband Cell line 2log ratio SAM q-value
NM_018674 ACCN4 2q35 PC346C 0.7 0.000
NM_004457 ACSL3 2q34-q35 PC346Flu1 2.0 0.000
NM_014109 ATAD2 8q24.13 PC346Flu1 0.8 0.000
AK027213 BBS10 12q21.2 PC346Flu1 0.8 0.000
NM_020235 BBX 3q13.1 PC346Flu1 0.8 0.007
AK024850 C2orf31 2q34 PC346Flu1 1.3 0.000
NM_006079 CITED2 6q23.3 PC346Flu1 1.0 0.000
AK026498 CYP2U1 4q25 PC346Flu1 1.5 0.000
NM_012062 DNM1L 12p11.21 PC346Flu1 1.4 0.000
NM_018456 EAF2 3q13.33 PC346Flu1 2.3 0.000
AK026517 EHF 11p12 PC346Flu1 0.6 0.000
AK022827 EIF2C3 1p34.3 PC346C / PC346Flu1 0.6 / 1.0 0.056 / 0.000
NM_012081 ELL2 5q15 PC346Flu1 / PC346Flu2 1.8 / 1.0 0.000 / 1.093
AF111849 ELOVL5 6p21.1-p12.1 PC346Flu1 1.5 0.000
AB020637 ENDOD1 11q21 PC346Flu1 / PC346Flu2 1.3 / 1.1 0.000 / 1.093
NM_019018 FAM105A 5p15.2 PC346Flu1 1.0 0.000
AK024648 FAM107B 10p13 PC346Flu1 0.8 0.007
AL137343 FAM84A 2p24.3 PC346Flu1 1.1 0.000
NM_004117 FKBP5 6p21.3-21.2 PC346C / PC346Flu1 / PC346Flu2 1.9 / 4.2 / 1.7 0.000 / 0.000 / 1.093
AK024715 FLJ21062 * 7q21.13 PC346Flu1 1.4 0.000
NM_020474 GALNT1 18q12.1 PC346Flu1 0.8 0.000
NM_005271 GLUD1 10q23.3 PC346Flu1 1.1 0.000
NM_002069 GNAI1 7q21 PC346Flu1 0.9 0.000
AB042410 GPR88 1p21.3 PC346C / PC346Flu1 / PC346Flu2 1.4 / 3.0 / 2.6 0.000 / 0.000 / 0.125
NM_001530 HIF1A 14q21-q24 PC346Flu1 1.2 0.000
NM_003543 HIST1H4H 6p21.3 PC346Flu1 1.7 0.000
M60721 HLX 1q41-q42.1 PC346Flu1 / PC346Flu2 0.7 / 0.6 0.000 / 1.093
NM_014642 IQCB1 3q13.33 PC346Flu1 0.8 0.139
NM_002241 KCNJ10 1q22-q23 PC346C 0.7 0.056
AL137384 KIAA1109 4q27 PC346C 0.6 0.027
NM_001206 KLF9 9q13 PC346Flu1 0.8 0.000
AF188747 KLK2 19q13.41 PC346C / PC346Flu1 / PC346Flu2 0.8 / 1.1 / 1.0 0.000 / 0.000 / 1.093
AK026375 LOC93622 * 4p16.1 PC346Flu1 1.0 0.000
NM_005461 MAFB 20q11.2-q13.1 PC346Flu1 1.1 0.000
NM_003010 MAP2K4 17p11.2 PC346Flu1 0.8 0.000
AB050049 MCCC2 5q12-q13 PC346Flu1 1.1 0.000
AK021627 MORC4 Xq22.3 PC346Flu1 1.2 0.000
AF142409 MS4A6A 11q12.1 PC346Flu1 0.8 0.450
NM_005956 MTHFD1 14q24 PC346C 0.6 0.000
NM_016498 MTP18 * 22q PC346C 0.6 0.000
NM_000662 NAT1 8p23.1-p21.3 PC346Flu1 1.7 0.000
AF039944 NDRG1 8q24.3 PC346Flu1 1.6 0.000
NM_006096 NDRG1 8q24.3 PC346Flu1 2.6 0.000
AK026383 NDRG1 8q24.3 PC346Flu1 2.1 0.000
NM_005596 NFIB 9p24.1 PC346Flu1 0.8 0.077
NM_020529 NFKBIA 14q13 PC346C / PC346Flu1 / PC346Flu2 0.7 / 2.4 / 0.7 0.000 / 0.000 / 1.093
NM_016590 PART1 * 5q12.1 PC346Flu1 1.5 0.000
NM_006810 PDIA5 3q21.1 PC346C / PC346Flu1 0.5 / 1.4 0.000 / 0.000
NM_016166 PIAS1 15q PC346Flu1 1.3 0.000
AF070670 PPM1A 14q23.1 PC346Flu1 0.7 0.000
AR Pathway in Therapy-Resistant PCa Cells
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23144
differentiation (Fig. 3A). The largest category includes genes
encoding for transcription factors and transcription regulators, such
as NFIB, KLF9, HIF1A, MAFB, EHF, NCOR1, NCOR2, PIAS1
and several zinc finger proteins (ZNF189, ZBTB10, ZBTB16 and
CASZ1). This was followed by genes involved in intracellular signal
transduction, including the G protein-coupled receptors pathway
(GPR88, RGS2, GNAI1), small GTPases of the Ras family (RHOB,
RHOU), mitogen-activated protein kinase cascade (MAP2K4,
MKNK2, TRIB1) and other protein kinases/phosphatases
(PPM1A, PPP2CB, PIK3R3, SGK1). Other AR responsive genes
have an effect on cellular proliferation through regulation of cell
cycle and apoptotic processes (e.g. RCC1, BBX, BIK, TP53INP1).
Concomitant with the role of androgens on prostate development
and maturation, another major cluster included genes involved in
cellular differentiation, such as TPD52, TWSG1, NDRG1, ID1
and ID3. Finally, androgen induced the metabolism of proteins,
carbohydrates and lipids that contribute to the production and
secretion of prostatic fluid. Such R1881 target genes included
MTHFD1, PSPH, PSAT1 and MCCC2, encoding enzymes in the
metabolism of methionine, serine and leucine amino acids,
respectively. Furthermore, up-regulation of the translation initiation
factor EIF2C3 potentially promotes peptide synthesis. Moreover,
genes participating in protein folding (PDIAS5, FKBP5), glycosyl-
ation (FUT8, GALNT1) and trafficking (DMN1L, KDELR2) were
also regulated by R1881. Apart from proteins and amino acids,
prostatic fluid is also rich in lipids, polyamines, sorbitol and several
metal ions. Indeed, R1881 also stimulated expression of ACSL3 and
ELOVL5, which participate in the elongation of fatty-acids,
spermine synthase (SMS), part of the polyamine synthetic pathway,
sorbitol dehydrogenase (SORD), secreted by the prostate into the
seminal fluid, and the ion channels ACCN4 and KCNJ10.
To automate the functional classification, quantify the degree of
enrichment of each cluster and select statistically significant
functional categories we used the DAVID Functional Annotation
Clustering tool. This tool identified 6 statistically significant
Annotation Clusters, which associated with the metabolism of
organic acids (lipids and amino acids), apoptosis, cell differentia-
tion, developmental processes, regulation of transcription and
regulation of cellular processes (Table 8).
The involvement of androgen-regulated genes in pathological
conditions was further investigated by using the Ingenuity
database (IngenuityH Systems, www.ingenuity.com). The strongest
associations were found for cancer, reproductive system, derma-
tological and cardiovascular diseases (Fig. 3B).
The AR pathway in prostate cancer development and
progression
To investigate how the AR pathway is modulated during the
development and progression of prostate cancer we linked our
androgen-regulated gene signature to seven independent prostate
cancer microarray databases. These studies included specimens of
‘‘normal prostate’’ and prostate tumors from diverse disease stages,
whose main characteristics are summarized in Table 7. A total of
89 hormone-responsive genes were present in at least 4 of the 7
GenBank ID HUGO_Symbol Cytoband Cell line 2log ratio SAM q-value
NM_004156 PPP2CB 8p12-p11.2 PC346Flu1 0.9 0.000
NM_002923 RGS2 1q31 PC346Flu2 0.7 0.000
D16875 RHOB 2p24 PC346Flu1 1.6 0.000
AK001478 RHOU 1q42.11-q42.3 PC346C / PC346Flu1 / PC346Flu2 0.8 / 2.3 / 1.0 0.000 / 0.000 / 0.000
AB051826 RHOU 1q42.11-q42.3 PC346Flu1 2.5 0.000
NM_005627 SGK1 6q23 PC346Flu1 0.9 0.000
AB040914 SHROOM3 4q21.1 PC346Flu1 1.0 0.012
NM_004595 SMS Xp22.1 PC346Flu1 1.1 0.000
NM_003082 SNAPC1 14q22 PC346Flu1 0.6 0.166
NM_003104 SORD * 15q15.3 PC346Flu1 1.2 0.000
NM_012449 STEAP1 7q21 PC346C / PC346Flu1 / PC346Flu2 0.8 / 1.7 / 1.0 0.000 / 0.000 / 1.093
AK026813 STEAP2 7q21 PC346Flu1 / PC346Flu2 1.1/ 0.7 0.000 / 0.000
NM_005656 TMPRSS2 21q22.3 PC346C 0.6 0.117
NM_005079 TPD52 8q21 PC346Flu1 / PC346Flu2 1.2 / 0.7 0.000 / 0.208
AF294628 TWSG1 18p11.3 PC346Flu1 1.0 0.000
NM_003115 UAP1 1q23.3 PC346Flu1 1.0 0.000
NM_003359 UGDH 4p15.1 PC346C / PC346Flu1 0.6 / 1.9 0.098 / 0.000
AK001647 USP40 2q37.1 PC346C 0.7 0.000
AB020676 WWC1 5q34 PC346Flu1 0.7 0.000
AK022814 ZBTB10 8q13-q21.1 PC346Flu1 / PC346Flu2 1.3 / 0.5 0.000 / 1.093
NM_006006 ZBTB16 11q23.1 PC346C / PC346Flu1 / PC346Flu2 0.9 / 1.6 / 1.5 0.000 / 0.000 / 1.093
AF025771 ZNF189 9q22-q31 PC346Flu1 1.5 0.000
AL157445 PC346Flu1 1.0 0.007
D17210 PC346Flu1 1.0 0.000
*no approved HUGO symbol exist for this entry. If present, UNIGENE symbol is given in alternative.
doi:10.1371/journal.pone.0023144.t003
Table 3. Cont.
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databases, and were selected for further analysis. In figure 4, we
show the hierarchical clustering of the R1881-responsive genes
(first block of 4 columns), next to primary cancer versus normal
prostate (second block), metastasis versus primary cancer (third
block), and finally recurrent versus non-recurrent and hormonal
therapy-resistant versus hormone-naı¨ve disease (fourth block). The
clustering analysis revealed four major gene groups: R1881-
repressed and up-regulated during progression to metastatic
disease (Cluster 1), R1881-repressed and down-regulated during
progression (Cluster 2), R1881-induced and down-regulated
Table 4. List of genes down-regulated by R1881.
GenBank ID HUGO_Symbol Cytoband Cell line 2log ratio SAM q-value
NM_005688 ABCC5 3q27 PC346Flu1 20.7 0.282
AK026288 ATHL1 11p15.5 PC346Flu1 21.0 0.008
NM_012342 BAMBI 10p12.3-p11.2 PC346Flu1 21.0 0.000
NM_001197 BIK 22q13.31 PC346Flu1 20.8 0.112
AF075110 C14orf4 14q24.3 PC346Flu1 21.3 0.000
NM_017766 CASZ1 1p36.22 PC346Flu1 21.0 0.112
NM_001305 CLDN4 7q11.23 PC346Flu1 20.6 0.282
AK024378 FAM131A 3q27.1 PC346Flu1 20.7 0.052
NM_004480 FUT8 14q24.3 PC346Flu1 21.0 0.316
NM_002165 ID1 20q11 PC346Flu1 / PC346Flu2 20.8 / 21.1 0.018 / 1.087
X69111 ID3 1p36.13-p36.12 PC346Flu1 21.3 0.000
NM_006769 LMO4 1p22.3 PC346Flu1 20.8 0.000
NM_017572 MKNK2 19p13.3 PC346Flu1 20.7 0.088
NM_005377 MYCL2 Xq22-q23 PC346C 21.0 0.116
NM_006312 NCOR2 12q24 PC346Flu1 20.6 0.052
U90907 PIK3R3 1p34.1 PC346Flu1 21.0 0.008
AF113132 PSAT1 9q21.2 PC346Flu1 20.8 0.000
NM_004577 PSPH 7p15.2-p15.1 PC346Flu1 20.9 0.041
NM_015923 SLC3A2 11q13 PC346Flu1 20.6 0.263
NM_003943 STBD1 4q24-q25 PC346Flu1 20.8 0.022
NM_003714 STC2 5q35.1 PC346Flu1 20.6 0.088
AK000401 TANC1 2q24.2 PC346Flu2 20.7 1.087
AL133074 TP53INP1 8q22 PC346Flu1 21.3 0.000
NM_003287 TPD52L1 6q22-q23 PC346Flu1 20.7 0.402
AF205437 TRIB1 8q24.13 PC346Flu1 21.6 0.000
U55055 PC346Flu2 21.0 1.087
NM_018588 PC346C / PC346Flu1 20.6 / 20.6 0.194 / 0.422
AK022971 PC346Flu1 20.7 0.450
AK022971 PC346Flu2 20.7 1.087
doi:10.1371/journal.pone.0023144.t004
Table 5. List of genes up-regulated by hydroxyflutamide.
GenBank ID HUGO_Symbol Cytoband Cell line 2log ratio SAM q-value
AB020637 ENDOD1 11q21 PC346Flu2 0.6 0.158
NM_004117 FKBP5 6p21.3-21.2 PC346Flu2 0.7 0.226
AB042410 GPR88 1p21.3 PC346Flu2 1.9 0.000
AK025585 PARS2 1p32.2 PC346Flu2 0.8 0.296
NM_019091 PLEKHA3 2q31.2 PC346Flu2 0.7 0.158
NM_002923 RGS2 1q31 PC346Flu2 0.6 0.000
AK026813 STEAP2 7q21 PC346Flu2 0.6 0.118
D17099 PC346Flu2 0.9 0.926
doi:10.1371/journal.pone.0023144.t005
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during progression (Cluster 3), R1881-induced and up-regulated
during progression (Cluster 4). About one third of the R1881-
regulated genes was differentially-expressed between primary
tumors and normal prostate in at least two databases. To this
group contributed mainly R1881-induced genes that showed up-
regulation in prostate cancer. These are genes that play a role in
the production of prostatic fluid and in secretory function of the
prostate, including SORD, ACSL3, ELOVL5, FKBP5, PDIA5,
GLUD1 and UAP1. However, when comparing metastatic cancer
to primary tumors, 23 of the R1881-induced genes were down-
regulated (Fig. 4, Cluster 3), while 11 androgen-repressed genes
were up-regulated (Fig. 4, Cluster 1). In total, these two clusters
made up a considerable fraction (40%) of the androgen-responsive
genes, and their expression pattern in metastasis suggests that the
AR pathway is selectively down-regulated at this stage of the disease.
In contrast, another group of R1881-stimulated genes showed
increased expression in metastasis compared to primary tumors
(Fig. 4, Cluster 4). This cluster is enriched for genes involved in
survival/cellular proliferation (MAFB, ELL2, TPD52, EHF,
HIF1A, HLX and SGK) and cell remodeling/adhesion (RHOU,
SHROOM3, MORC4, TWSG1). Conversely, a group of R1881-
repressed genes down-regulated in metastasis included genes
involved in cellular differentiation and development (ID1, ID3,
LMO4 and TPD52L1) (Fig. 4, Cluster 2). Finally, we assessed the
activation state of the AR pathway in recurrent and in hormonal
therapy-resistant disease. The collection of datasets in this category
is limited to three non-concordant databases: Best et al. and Tamura
et al. compared hormone-naı¨ve with hormonal therapy-resistant
samples, Singh et al. evaluated biochemical recurrence following
radical prostatectomy. Therefore, the overlap between the three
databases was modest. Nevertheless, the general trend is the same as
for the progression of primary cancer to metastatic disease: genes
down-regulated in metastasis tend to be down-regulated in
recurrent versus non-recurrent and/or hormonal therapy-resistant
versus homone-naı¨ve disease, and vice-versa. These results suggest
that the common mechanisms may govern the progression to
different states of prostate cancer disease.
AR target genes as markers for disease diagnosis and
prognosis
The last objective of this study was to identify genes that could
possibly be used as markers in the diagnosis of prostate cancer or
in predicting the course of disease. We selected three R1881-
regulated genes to be analyzed by quantitative PCR on normal
prostate and prostate carcinoma samples obtained in our institute:
ACSL3, MCCC2 and ENDOD1. The human prostate specimens
obtained in our institute have been previously validated for marker
research [14]. For this purpose, the well-known prostate cancer
markers Hepsin and AMACR have been tested as positive controls
[28,29]. Both markers showed significantly higher expression in
the prostate carcinoma than in the normal prostate samples,
confirming that our panel is representative and suitable for the
research of novel diagnostic/ prognostic markers [14]. The
candidate genes were selected based on their strong androgen-
induction, potential pathological function but, most importantly,
on the fact that their expression was confirmed to be altered across
multiple prostate cancer databases analyzed (Fig. 4B). In this sense,
ACSL3 seems to be slightly up-regulated in primary prostate
tumors and strongly repressed in metastatic cancer. Furthermore,
fusion of the ACSL3 gene to the ETS family member ETV1 has
recently been reported, making it an interesting gene for follow-up
[30]. MCCC2 was strongly up-regulated in primary cancer,
although its expression in metastasis and hormonal therapy-
resistant disease varies in the different databases (Fig. 4B). Finally,
ENDOD1 was one of the strongest R1881-induced genes in our
microarray profile, and showed decreased expression in metastasis
and therapy-resistant tumors, suggesting a possible role in disease
progression (Fig. 4B).
Quantitative PCR analysis included 21 samples of normal
prostate tissue (adjacent to cancer), 73 primary prostate tumors
and 13 lymph node metastasis. The primary tumors consist of 52
low-grade samples (Gleason 5–7), 21 samples from late-stage
poorly-differentiated tumors (Gleason 8–10) and 9 hormonal
therapy-resistant specimens, obtained from patients operated by
radical prostatectomy or transurethral resection of the prostate
(TURP). ACSL3 expression was significantly decreased during
progression from low-grade to high-grade tumors (P = 0.005;
Fig. 5A). ENDOD1 exhibited a stepwise down-regulation during
disease progression (P,0.05 for Post linear-trend test), which is
consistent with the results from the prostate cancer databases
(Fig. 5B). Finally, MCCC2 was up-regulated in well-differentiated
tumors (P,0.005), but its expression decreased during progression
to high-grade cancer (P,0.05; Fig. 5C). This biphasic expression
of MCCC2 during prostate cancer progression might explain the
variation observed across the different databases mentioned above.
Furthermore, expression of all three candidate genes was
decreased during progression to therapy-resistant disease, although
the trend for MCCC2 was not statistically significant.
Discussion
In order to design better diagnostic and prognostic tools for
prostate cancer and to develop more efficient therapies for late
stage disease, it is essential to methodically understand the
processes by which this disease develops and progresses. In this
sense the AR pathway is of great interest for clinicians, researchers
and pharmaceutical industry as it plays a crucial role in prostate
malignancy. To investigate whether the AR pathway is function-
ally active in hormonal therapy-resistant prostate disease, we
Table 6. List of genes down-regulated by hydroxyflutamide.
GenBank ID HUGO_Symbol Cytoband Cell line 2log ratio SAM q-value
NM_014805 EPM2AIP1 3p22.1 PC346Flu2 20.8 0.301
NM_006854 KDELR2 7p22.1 PC346C 20.8 0.118
AB028451 NCOR1 17p11.2 PC346Flu2 21.2 0.301
AB046842 PPP4R4 14q32.12-q32.13 PC346Flu2 -0.7 0.301
NM_001269 RCC1 1p36.1 PC346Flu2 20.7 0.301
NM_000370 TTPA 8q13.1-q13.3 PC346Flu2 20.9 0.301
doi:10.1371/journal.pone.0023144.t006
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started by establishing the expression program of AR target genes
in PC346 cell lines stimulated with R1881 or hydroxyflutamide.
R1881 stimulation of the androgen-sensitive PC346C subline
resulted in differential expression of 20 genes, including the well-
known AR target genes TMPRSS2, KLK2 and TPD52.
Consistent with the expression of wild-type AR, OH-flutamide
did not mediate transcription of AR-target genes in PC346C cells.
The castration-resistant PC346DCC subline, which expresses
very low levels of the receptor, showed to be insensitive to R1881
stimulation. These results suggest that the AR pathway is not
essential for the growth of PC346DCC cells. Alternative survival
and growth pathways involved in the AR bypass in PC346DCC
are under investigation and were recently published elsewhere
[31].
Conversely, the cell line overexpressing the AR, PC346Flu1,
showed a ‘‘super-activation’’ of the pathway, not only in the
number of regulated genes but also in the strength of this
regulation. This reveals two important aspects: (i) although these
cells have been cultured in the absence of androgens for longer
than two years, the AR is still functional and can be activated by
the presence of its ligand; (ii) the AR seems to be hyper-sensitive,
likely due to the high levels of the receptor, which may be sufficient
to support cell growth under the hormone-depleted conditions.
Interestingly, PC346Flu1 proliferation is inhibited by physiological
concentrations of androgens, both in vivo and in vitro, suggesting
that AR ‘‘super-activation’’ is unfavorable for cell growth, possibly
by inducing cellular differentiation [8]. This is in line with a
previous report, which showed that prostate epithelial cells tolerate
a narrow-range of AR expression and activity, by undergoing
apoptosis in the absence of AR expression and cell cycle arrest
upon AR hyper-stimulation [32]. How AR overexpression can
lead to receptor activation under androgen-depleted conditions is
still not fully understood. Hypothetically, there are two possible
mechanisms: increased sensitivity to residual androgen levels or
constitutive ligand-independent activation. Some authors have
proposed that increased AR levels not only sensitised the receptor
to residual androgen concentrations but also conferred agonistic
activity to AR antagonists [33,34]. However, previous results
showed that PC346Flu1 proliferation was optimal in the absence
of androgens and was unaffected by flutamide supplementation
[8]. The lack of agonistic activity of flutamide on PC346Flu1 cells
was further confirmed in the present expression microarray
analysis. Likewise, Konkontis et al. also failed to replicate the
antagonist to agonist conversion in hormone-refractory LNCaP-
104R cells, which express 15-fold more AR protein that respective
androgen-sensitive parental LNCaP-104S cells [35,36]. These
results suggest that the proliferation of PC346Flu1 cells is not
dependent on residual androgens, but is maintained by constitu-
tive AR activation resistant to AR antagonists. This view is
supported by findings from Dehm et al., which, by introducing
disabling mutations in the ligand-binding domain, showed that
ligand binding was not necessary for constitutive AR activation in
C4-2 cells [37]. The authors also observed increased transactiva-
tion activity of the AR N-terminal domain in these cells, compared
to parental LNCaP. Similar processes could be playing a role in
constitutive AR activation in PC346Flu1 cells. In contrast, a recent
report by Waltering et al., supports the hypothesis of increased
sensitivity to residual androgen levels upon 2 to 4 times (LNCaP-
ARmo) and 4 to 6 times (LNCaP-ARhi) LNCaP- AR overexpres-
sion [38]. Additionally, the authors also analysed the androgen
response of these cell lines by expression microarrays. About 2/3
of the AR-regulated genes in our signature were also regulated
upon DHT treatment of LNCaP-ARmo and/or LNCaP-ARhi. In
particular, this included genes involved in secretory pathways, lipid
and sugar metabolism (such as, UGDH, SORD, GLUD1,
ELOVL5, ASCL3, UAP1), but also genes implicated in tumor
progression and metastasis with functions in cell survival,
proliferation and adhesion (EHF, ELL2, TPD52, MAFB, SGK).
Figure 1. Validation of the microarray results. Quantitative RT-PCR analysis of a set of 10 androgen-regulated genes in PC346 cell lines. Cells
were stimulated with 1 nM R1881 (R1881), 1 mM OH-flutamide (Flut) or vehicle control (DCC-FCS) for 16h. The graphs show the Mean (6 SE) of the
normalized gene expression (n.g.e.) relative to the housekeeping gene GAPDH, for two independent cell passages. ID3 and TRIB1 were androgen-
repressed in the microarray assays, whereas the other genes were up-regulated by androgens.
doi:10.1371/journal.pone.0023144.g001
Table 7. Description of the androgen-regulation and prostate cancer databases linked via SRS.
First Author (date) Reference sample(s) Query
DePrimo (2002) [13] LNCaP, LN95, LN96, LN97, LN98, LAPC, MDA2a
and MDA2b cell lines
1nM R1881, 10nM DHT, 100nM DHT and 1000nM DHT different time
points from 7 to 72h
Hendriksen (2006) [14] LNCaP 1nM R1881 time-course from 2h to 120h
Nelson (2002) [15] LNCaP 24h and 48h 1nM R1881
Nickols (2007) [16] LNCaP 16h 1nM DHT
Wang (2007) [17] LNCaP 4h and 16h 100nM DHT
Best (2005) [18] 10 hormone-naive prostate cancers 10 hormone-refractory primary prostate tumors
Chandran (2007) [19] 64 primary prostate tumor samples 24 hormone-refractory metastatic samples from 4 patients
Lapointe (2004) [20] 41 benign prostate tissue adjacent to cancer 62 primary prostate tumor samples and 9 lymph node metastasis
Singh (2002) [21] 50 benign prostate tissue adjacent to cancer 52 primary prostate tumor samples: 8 recurrent and 13 non-recurrent (.4
years) after radical prostatectomy
Tamura (2007) [22] 10 hormone-naive prostate cancers 18 hormone-refractory primary and metastatic samples
Varambally (2005) [23] 4 benign prostate tissues 5 clinically localized prostate cancers and 5 metastatic samples
Yu (2007) [24] 60 benign prostate tissue adjacent to cancer and
23 disease free donor prostate tissue
62 primary prostate tumors and 24 metastatic samples from 4 patients
doi:10.1371/journal.pone.0023144.t007
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Figure 2. Expression profile of androgen-responsive genes in PC346 cells linked to publicly available databases on AR
transcriptional regulation. On the left side, PC346C, PC346Flu1 and PC34Flu2 were exposed to 1 nM R1881 or 1 mM OH-flutamide for 4, 8 and 16h,
whereas PC346DCC was stimulated with 1 nM R1881 only. On the right side, our gene signature was assessed in the databases from DePrimo et al.,
Nelson et al., Nickols et al., Wang et al. and Hendriksen et al. (see Table 7 for database details). Heat-map is presented for the 2log expression ratio
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All together, AR overexpression may lead to different mechanisms
of activation, depending on the background of the cells, the type or
the duration of the androgen-depletion treatment.
In PC346Flu2 subline, carrying a mutated receptor, transcrip-
tion of AR-target genes was regulated by both R1881 and OH-
flutamide, although the stimulatory effect of the latter was weaker.
This is in agreement with the agonistic action of OH-flutamide on
the T877A mutated AR in promoting rather than inhibiting the
growth of PC34Flu2 cells [8,39].
In general, from these analyses we can conclude that the AR
pathway is modified and still able to respond to stimuli, in the
majority of therapy-resistant prostate cancer cells subjected to
long-term androgen ablation. Furthermore, it is worth noting how
the AR transcription patterns of the three therapy-resistant
sublines reflected their respective AR modifications and growth
characteristics. AR down-regulation correlated with deficient
activation of AR-target genes; high-levels of AR resulted in more
differentially-expressed genes and stronger regulation upon R1881
stimulation; finally, the T877A mutated AR responded to both
R1881 and hydroxyflutamide.
To investigate the biologic processes coordinated by the AR
target genes we used DAVID and Ingenuity tools to extract and
cluster Gene Ontology Annotations. Consistent with the physio-
logical roles of androgens in prostate development and matura-
tion, the selected gene-signature is enriched for functions in
transcription regulation, intracellular signal transduction, differ-
entiation and regulation of cell proliferation and cell death.
Further functions are associated with the metabolism of proteins,
lipids and carbohydrates, which can be related to the production
and secretion of prostatic fluid. Pathway analysis using Ingenuity
showed strong association of the androgen-regulated genes to
pathological conditions as cancer, reproductive system, dermato-
logical and cardiovascular diseases (Fig. 3 and Table 8).
Next we evaluated the role of the AR pathway in prostate
cancer development and how it is modulated during cancer
progression by linking our androgen-regulated gene signature to
seven previously published microarray databases on clinical tumor
samples. Together, these databases comprise 178 ‘‘normal
prostate’’ samples and 331 malignant specimens, including
metastasis, recurrent tumors and hormonal therapy-resistant
between hormone-treated samples and respective time-matched vehicle controls. Red and green colors represent induction and repression,
respectively, whereas black indicates no regulation. Grey squares indicate missing data due to low expression, poor data quality or absence of probes
for the respective transcript in the array platform used for the study.
doi:10.1371/journal.pone.0023144.g002
Figure 3. Biological processes regulated by the selected androgen-target genes. (A) Pie-graph representing genes categorized according
to most prominent biological function. Gene ontology annotations were extracted using DAVID [25,26]. (B) Involvement of the AR pathway genes in
disease determined using Ingenuity Pathway Analysis (IngenuityH Systems, www.ingenuity.com).
doi:10.1371/journal.pone.0023144.g003
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samples (Table 7). It is worth noting that the definition of ‘‘normal
prostate’’ is not the same across the different studies. While most
authors used benign tissue adjacent to the tumor as the ‘‘normal"
reference, Yu et al. used normal prostatic epithelia from individuals
without evidence of prostatic disease [24]. They showed that the
expression profile of prostate cells was not only altered within the
tumor itself, but alterations were also detected in apparently
benign tissue around the borders of the tumor. This so-called field-
effect has been reported in various other studies, and it is believed
to be more evident the closer the distance to the tumor [28,40,41].
Disparity in the sampling of the ‘‘normal prostate’’ reference may
certainly contribute to the variation seen between the diverse
studies, together with differences in study design, microarray
platforms, and most importantly, in the characteristics of the
tumors included.
In summary, our AR-response profiling revealed that a
considerable fraction of AR pathway genes were up-regulated
in primary prostate cancer compared to normal prostate and
down-regulated in metastasis. Further inspection of this gene
cluster showed enrichment for genes involved in differentiation
and secretory function of the prostate, functions which are
redundant, if not detrimental for progressing cancer cells (Fig.4,
Cluster 3). On the other hand, the cluster of androgen-regulated
genes over-expressed in metastasis is enriched for genes involved
in cell survival, proliferation, cytoskeletal remodelling and
adhesion, all crucial functions in tumor progression and invasion
(Fig. 4, Cluster 4).
It is generally accepted that the AR pathway accounts for the
tumor growth in most prostate cancer patients even under
hormonal ablation therapy. This hypothesis is supported by
numerous reports that the AR itself is expressed in the majority of
prostate cancers and often amplified in metastasis and therapy-
resistant tumors [42,43,44,45,46]. Chen et al. have shown that AR
overexpression is the most common modification following
androgen ablation treatment, and is sufficient to confer hormonal
therapy-refractory growth [33]. Furthermore, clinical tumor
relapse is determined by PSA recurrence, which may give the
impression that the AR pathway has become again fully
functional. However, the results of our present study showed a
selective down-regulation of AR target genes, questioning the
Figure 4. Expression of androgen-responsive genes in prostate cancer samples from patients. (A) Heat-map representation of publicly
available expression data from human prostate cancer using the AR-regulated 107-genes signature (see Table 7 for database details). (B) Androgen-
responsive genes selected for further quantitative PCR analysis. PC: prostate cancer; NP: normal prostate; Met: metastatic samples; AD: androgen-
dependent; AI: hormonal therapy-resistant; (Non)Rec: (non)recurrent after radical prostatectomy. Color scheme as described for Figure 2.
doi:10.1371/journal.pone.0023144.g004
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over-simplistic view of the AR pathway as the driving force for
prostate cancer growth and proliferation. In fact, the raise in
serum PSA levels during relapse rather reflects the expansion of
the tumor burden than increased AR activity in the tumor tissue
self [47]. Indeed, Sterbis et al. reported that increased risk of
biochemical recurrence was associated with low expression of
tissue PSA mRNA [48]. Furthermore, the authors observed that
serum PSA levels did not correlate with tissue mRNA expression,
which was decreased in malignant compared to benign prostate
epithelial cells [48]. By using distinct cell lines to establish the
androgen-response signature and expanding the patient-derived
database sets, our results corroborate previous observations from
Hendriksen et al., which used the androgen-response expression
profile from LNCaP cells to interrogate a set of prostate cancer
xenografts and patient-derived samples [14]. Shortly thereafter,
with distinct bioinformatics approaches, two other studies
confirmed an attenuated androgen signaling signature in high-
grade and metastatic prostate cancer, indicating that down-
regulation of the AR pathway, although controversial, is likely to
be a true phenomenon [49,50].
The mechanisms for this selective modulation of the AR
pathway during prostate cancer progression are yet undefined, but
we speculate that it may be dictated by an imbalance in AR co-
regulators and/or interactions with other signaling pathways.
Indeed, alterations in several AR co-activators and co-repressors
have been previously detected in prostate cancer and, in
particular, in hormonal therapy-resistant disease [51,52]. Further-
more, crosstalk between the AR and other growth factor pathways
has been shown to activate AR signaling and selectively regulate a
fraction of the AR transcriptional program, in response to IGF
and EGF [53,54].
To accommodate these novel insights into our current knowledge
of prostate cancer disease, we propose the following model for the
development and progression of prostate tumors (Fig. 6): in the
normal prostate the AR maintains prostate homeostasis and
secretory functions through a delicate balance between cell survival
and differentiation. A yet unknown trigger leads to a switch from
androgen-dependent survival to androgen-stimulated cellular
proliferation. Recent findings implicate gene fusions between
androgen-regulated genes and ETS transcription factor family
members in this process. The TMPRSS2-ERG fusion is the most
frequent rearrangement, being detected in approximately 50% of
the prostate tumors [55]. The androgen-responsive promotor
region of the TMPRSS2 gene drives robust expression of ERG,
an oncogene that is also frequently involved in chromosomal
translocations in Ewing sarcoma, myeloid leukemia and cervical
carcinoma [56,57,58]. Up to date, multiple other ETS family
members and 59 fusion partners have been identified in related
rearrangements in prostate cancer [59,60,61,62]. However, the
biological role of ETS fusions in prostate cancer development is still
Table 8. Summary of significantly enriched Gene Ontology (GO) categories.
Annotation Cluster 1 Enrichment Score: 2.43 Count P-value
organic acid metabolic process 10 0.0025
amino acid metabolic process 7 0.0046
Gene list: ACSL3, ELOVL5, PSPH, SMS, UGDH, GLUD1, MTHFD1, PPP2CB, MCCC2, PSAT1
Annotation Cluster 2 Enrichment Score: 2.34 Count P-value
apoptosis 12 0.0019
programmed cell death 12 0.0021
Gene list: DNM1L, PPP2CB, ELL2, BIK, RHOB, MTP18, TPD52L1, TP53INP1, SGK1, NFKBIA, ID3, ZBTB16
Annotation Cluster 3 Enrichment Score: 2.27 Count P-value
developmental process 27 0.0088
cell differentiation 19 0.0042
Gene list: FUT8, MAFB, MTP18, TPD52L1, CITED2, TTPA, SHROOM3, EHF, LMO4, NDRG1, TP53INP1, SGK1, BIK, RHOB, ZBTB16, UGDH, IQCB1, ID1, ID3, ELL2, DNM1L, HLX,
KLF9, PPP2CB, TPD52, TWSG1, NFKBIA
Annotation Cluster 4 Enrichment Score: 2.12 Count P-value
regulation of developmental process 7 0.002
hemopoiesis 5 0.016
Gene list: MAFB, PPP2CB, TWSG1, NFKBIA, ZBTB16, SHROOM3, IQCB1
Annotation Cluster 5 Enrichment Score: 1.69 Count P-value
negative regulation of metabolic process 7 0.023
negative regulation of transcription 6 0.018
Gene list: PPP2CB, ZNF189, NCOR1, NCOR2, ID1, ID3, ZBTB16
Annotation Cluster 6 Enrichment Score: 1.49 Count P-value
regulation of cellular process 31 0.014
regulation of gene expression 23 0.017
Gene list: TP53INP1, SNAPC1, TPD52L1, ZBTB16, NFKBIA, ZBTB10, LMO4, NFIB, PIAS1, MKNK2, EHF, NCOR1, NCOR2, MAFB, KLF9, BIK, RHOB, BBX, ID1, ID3, HLX, ZNF18,
TWSG1, IQCB1, PPM1A, RGS2, CITED2, PPP2CB, HIF1A, CASZ1, RCC1
doi:10.1371/journal.pone.0023144.t008
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controversial, since ERG and ETV1 by themselves, do not seem to
be tumorigenic [60,63]. Recent evidence suggests that ERG
overexpression cooperates with PTEN loss in the progression from
PIN to prostate adenocarcinoma [64,65]. It is worth noting that
PC346 cells do not carry the TMPRSS2-ERG or TMPRSS2-
ETV1 fusions, nor show increased expression of these oncogenes
(unpublished data). Therefore, it remains unclear which mechanism
may drive androgen-sensitive growth of PC346C cells. Nevertheless,
it is still possible that other less common fusions partners that we did
not test yet may be involved. We hypothesize that at early stages,
when tumors are well differentiated, expression of prostate-specific
genes and genes involved in the production/secretion of prostatic
fluid is maintained or even increased due to the growth of the
epithelial cell compartment. As tumors progress and become more
aggressive, genes involved in prostate differentiation and secretory
function are selectively repressed, while genes promoting prolifer-
ation are up-regulated. This mechanism will eventually culminate in
a fast-growing, poorly-differentiated late-stage disease (Fig. 6). Upon
hormone therapy, cells may become resistant and resume growth by
adaptations of the AR pathway and/or activation of alternative
growth pathways (Fig. 6. Reviewed in [7]). Our cell line model
represents two of these AR modifications: AR mutation
(PC346Flu2) and AR overexpression (PC346Flu1), as well as AR
pathway bypass through activation of oncogenes and tumor
suppressor down-regulation (PC346DCC) [31]. However, AR
knockdown experiments suggest that the AR pathway may remain
vital for most therapy-refractory cells, as it induced apoptosis and
inhibited growth of multiple castration-resistant cell lines and
xenografts [66,67,68,69,70,71].
In order to identify androgen-regulated genes that could
possibly be used in the diagnosis/prognosis of prostate cancer,
we selected from our 107-gene signature three androgen-regulated
genes: MCCC2, ENDOD1 and ACSL3. Quantitative PCR
analysis showed increased MCCC2 expression in early-stage,
well-differentiated tumors, while ENDOD1 and ACSL3, were
decreased in late-stage tumors and metastasis. In addition, we
analyzed immunohistochemical data made available by the
Human Protein Atlas, to check the expression of the cognate
proteins in tumor samples. The Human Protein Atlas portal is a
publicly available database with high-resolution images showing
the spatial distribution of proteins in 46 different normal human
tissues and 20 different cancer types, as well as 47 different human
cell lines (www.proteinatlas.org). Data on ACSL3, MCCC2 and
ENDOD1 protein expression is available for 3 normal tissue
samples and 11 prostate tumors. Immunohistochemical staining
showed moderate to strong cytoplasmic positivity in the glandular
prostate cells for all the three potential markers. These results
confirm that the candidate genes are indeed translated into
proteins that can be detected in the tumor samples, which makes
the development of potential diagnostic/prognostic assays feasible.
To assess the prognostic value of these genes we compared
primary prostate cancer that eventually developed distant
metastasis after radical surgery with the non-recurrent tumors,
but saw no significant differences (data not shown). Ultimately, the
large inter-individual variation resulted in a poor separation
between the diverse disease stages, even when the differences in
expression were statistically significant. This limits the applicability
of MCCC2, ENDOD1 or ACSL3 as independent diagnostic
markers, by preventing the setting of an expression cutoff with
both high specificity and sensitivity. However, the performance of
these candidates may be improved in combination with other
disease markers, such as PSA or ETS gene fusions, which has yet
to be further evaluated in the diagnosis and prognosis of prostate
cancer. Finally, the down-regulation of all three candidate genes in
hormonal therapy-resistant compared to hormone-naı¨ve disease is
in agreement with an attenuation of the AR pathway, providing
important clues on the mechanisms of prostate cancer progression.
In conclusion, the present study showed that castration-resistant
PC346 cells maintained a transcriptional response to (anti)androgen
stimulation, which was in accordance with the expressed AR
modifications. By linking AR modifications with enhanced tran-
scriptional function in therapy-resistant PCa cells, these results
corroborate the hypothesis that the AR pathway is adapted and
active in most cells refractory to hormonal therapy. The present
study also showed that the AR pathway is selectively modulated
during PCa progression, leading to repression of genes involved in
cellular differentiation and up-regulation of anti-apoptotic and
proliferation genes. The AR-responsive gene signature reported here
Figure 5. Quantitative RT-PCR analysis of three androgen-
responsive genes ACSL3, ENDOD1 and MCCC2 in a distinct set
of prostate samples. NAP: normal adjacent prostate; LG-PC: low-
grade prostate cancer, including Gleason score from 5-7; HG-PC: high-
grade prostate cancer, including Gleason score from 8-10; LNmet:
lymph-node metastasis; HNPC: hormone-naı¨ve prostate cancer (primary
site); HRPC: hormonal therapy-resistant prostate cancer (primary site);
(*) p-value #0.05 and (**) p-value #0.005 using Mann-Whitney two-
tailed test; (***) p-value #0.05 with Post linear-trend test.
doi:10.1371/journal.pone.0023144.g005
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provides a valuable tool to elucidate the mechanisms of this selective
adaptation of the AR signalling, as well as to investigate novel disease
markers for PCa progression and potential targets for therapy.
Links
Bioconductor [http://www.bioconductor.org]
DAVID Database [http://david.abcc.ncifcrf.gov]
Eisen Lab [http://rama.lbl.gov]
Gene Ontology Omnibus (GEO)[ http://www.ncbi.nlm.nih.
gov/geo/]
Ingenuity Pathway Analysis [http://www.ingenuity.com/]
Significance Analysis of Microarray Data [http://www-stat.
stanford.edu/˜tibs/SAM]
The Human Protein Atlas [http://www.proteinatlas.org/]
Supporting Information
Table S1 List of SAM significant genes for PC346C cell line.
(XLS)
Table S2 List of SAM significant genes for PC346DCC cell line.
(XLS)
Table S3 List of SAM significant genes for PC346Flu1 cell line.
(XLS)
Table S4 List of SAM significant genes for PC346Flu2 cell line.
(XLS)
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